X

Drug Profile

LTI 01

Alternative Names: LTI-01

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lung Therapeutics; University of Texas at Tyler
Developer Rein Therapeutics; University of Texas at Tyler
Class Antibacterials; Antifibrotics; Plasminogen activator enzymes; Thrombolytics
Mechanism of Action Fibrinolytic agents; Plasminogen activator inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Empyema
New Molecular Entity Yes

Highest Development Phases

Phase II Pleural effusion
Phase I Empyema

Most Recent Events

10 Jan 2025 Aileron Therapeutics is now called Rein Therapeutics
10 Jan 2025 Rein Therapeutics plans a phase IIb trial for Pleural effusion (Intrapleural)
01 Feb 2024 Phase-I development in Empyema and Pleural effusion in Australia and New Zealand (Intrapleural, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com